REG - ValiRx PLC - New Evaluation and Option Agreement

ValiRxAnnouncement

29/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250129:nRSc0325Va&default-theme=true

RNS Number : 0325V  ValiRx PLC  29 January 2025

29 January 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

New Evaluation and Option Agreement

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, and Altus Formulation Inc
("Altus") a Canada based drug development and delivery company, have entered
into an evaluation and option agreement to determine the value of Altus'
SmartCelle drug delivery technologies and novel anti-inflammatory compounds in
the treatment of cancer (the "Agreement") for an initial twelve month period.

Under the Agreement, ValiRx will assess the SmartCelle platform's ability to
enhance the solubility, potency and targeting of a series of drug candidates
including ValiRx's CLX001 cytolytic peptide and Altus' novel CB(2) agonist
TA-A001. The evaluation will be performed on a range of Patient Derived Cells
(PDCs) by ValiRx's subsidiary Inaphaea BioLabs, with lead candidates then
being tested in vivo through collaborative partners to assess safety,
biodistribution and efficacy. ValiRx has an option to license the technologies
for the treatment of certain cancers.

The period during which the option must be exercised is three months after the
date when a clinical development candidate is identified after which time no
such option will exist unless mutually agreed. Any clinical development
candidate would be subject to a separate license. The period for negotiation
of the terms of the separate license is limited to a period of three months
from the exercise of the option by ValiRx.

 

Mark Eccleston, CEO of ValiRx commented "In a first for ValiRx, we are
signing an evaluation agreement with a proprietary formulation technology
provider to develop novel drug/delivery combinations for both our own assets
as well as accessing preformulated assets from Altus. This builds on my
personal technical background in drug delivery and opens up a range of
possibilities to accelerate our development and evaluation programs."

Damon Smith, CEO of Altus commented "ValiRx's track record of accelerated drug
development makes them the ideal partner to validate SmartCelle and TA-A001 in
the oncology space. We look forward to working with Mark and the team in this
exciting new enterprise."

 

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/NPwQwe

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0025

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRLVLLLEFLLBBV